2009 update. Resectable disease Locally advanced disease Advanced disease. Supportive care Pancreatic neuro-endocrine tumours
|
|
|
- Kellie Singleton
- 8 years ago
- Views:
Transcription
1 Modern treatment of pancreatic cancer 2009 update Resectable disease Locally advanced disease Advanced disease Supportive care Pancreatic neuro-endocrine tumours Morten Ladekarl Department of Oncology Aarhus University Hospital Denmark
2 RESECTABLE DISEASE
3 RESECTABLE DISEASE Disease stage 5-year survival (%) Localized 15.2 Regional 6.8 Distant 1.8 SEER Cancer Statistics Review
4 CONKO-001, Gem vs observation RESECTABLE DISEASE Significant increase in median survival from 20 to 23 months Increase in est. 5-year 5 survival rate from 9% to 21% Beneficial effect in all subgroups Oettle et al., JAMA 2007 & Neuhaus et al., ASCO proceedings 2008
5 ESPAC 3 RESECTABLE DISEASE ESPAC 3: A multicenter, international, open label, randomized, controlled phase III trial of adjuvant 5 fluorouracil/folinic acid (5 FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. Neoptolemos et al., ASCO FU+ folinsyre i 5 dage hver 28. dag i 6 cyklus N= pt. Gemcitabin 1 gang om ugen i 6. cyklus N= arm BSC lukket præmaturt grundet signifikant effekt af Gem vs BSC. R0/R1 resektion < 8 uger efter operation
6 ESPAC 3 RESECTABLE DISEASE ESPAC 3: A multicenter, international, open label, randomized, controlled phase III trial of adjuvant 5 fluorouracil/folinic acid (5 FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. Neoptolemos et al
7 RESECTABLE DISEASE News 2009, adjuvant treatment Gem og 5FU er lige effektive,, men Gem er mindst toksisk GemCap vs. Gem er i fase III (ESPAC 4)
8 LOCALLY ADVANCED DISEASE
9 LOCALLY ADVANCED DISEASE Options Chemotherapy Gem Gem in combinations Chemoradiotherapy
10 LOCALLY ADVANCED DISEASE Overall survival on Gem Storinolo et al., Cancer 1998
11 Chauffert et al., LOCALLY ADVANCED DISEASE Phase III-study of Gem vs. 5FU/cisplatin-based CRT
12 LOCALLY ADVANCED DISEASE
13 LOCALLY ADVANCED DISEASE Chauffert et al., Phase III-study of Gem vs. 5FU/cisplatin-based CRT
14 LOCALLY ADVANCED DISEASE Loehrer et al., Phase III-study of Gem vs. Gem-based CRT
15 LOCALLY ADVANCED DISEASE Loehrer et al., Phase III-study of Gem vs. Gem-based CRT
16 Cis gem Dag 1, 8, 22, 29 Og cis gem efter KRT LOCALLY ADVANCED DISEASE Wilkowski et al. Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment of patients with locally advanced, nonmetastatic pancreatic cancer. ASCO forskellige kemo regimer med konkomittant strålebehandling á 50GY/25fr. Kontinuerlig 5FU 95 pt Cis gem Dag 1,8, 22, 29
17 LOCALLY ADVANCED DISEASE Final analysis of a multicenter, randomized phase II trial comparing three different chemoradiotherapy regimens in the treatment of patients with locally advanced, nonmetastatic pancreatic cancer. Ralf Wilkowski PFS (mdr) OS (mdr) Hæm.tox Diarre RKT-5FU 4 9,6 + RKT-GC 5,6 9,3 + RKT-GC + GC 6 7, patienter blev opereret. Fordeling ukendt! Højere frekvens af grad 3/4 hæmotologiske bivirkninger i GC armene Ingen forskel mellem 5FU og Gem/Cis.
18 LOCALLY ADVANCED DISEASE Konklusioner Stadig ikke afklaret om kemo-radioterapi forlænger overlevelsen i forhold til kemoterapi alene Ikke afklaret, hvilken kemoterapi der er bedst sammen med radioterapi Kemo-radioterapi kan i udvalgte tilfælde lde medføre konvertering af sygdom fra ikke-resektabel til resektabel, men det kan kemoterapi alene også
19 LOCALLY ADVANCED DISEASE Herrmann 2008
20 ADVANCED DISEASE
21 ADVANCED DISEASE Advanced disease Median survival untreated 3-4 months Primary goals of treatment Prolongation of survival Improvement in QoL
22 ADVANCED DISEASE Gemcitabine vs. 5-FU5 Gemcitabine 5-FU P Clinical benefit response* 24% 5% Median survival (months) Time to progression (months) month survival 46% 31% 1-year survival 18% 2% Partial response 5.4% 0% Stable disease 39.3% 19% *Composite of measurements of pain (analgesic consumption and pain intensity), Karnofsky performance status, and weight Burris H, et al. J Clin Oncol. 1997;15:
23 Survival of Gem-treated patients according to performance status ADVANCED DISEASE Storinolo et al., Cancer 1998
24 ADVANCED DISEASE Combination chemotherapy Gem-Cap JCO, october 2009
25 ADVANCED DISEASE Cunningham et al.: GEM-CAP Final analysis 2009 Interim analysis 2005 Hazard ratio: % CI: Log-rank p=0.026 Eur J Cancer Suppl 2005
26 ADVANCED DISEASE Meta-analysis analysis of GEM-CAP Cunningham et al., JCO 2009
27 Gem vs. Gem platinum ADVANCED DISEASE Di Miao. A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy naive advanced pancreatic adenocarcinoma: The GIP 1 (Gruppo Italiano Pancreas GOIM/GISCAD/GOIRC) study. ASCO pt. Gemcitabin ugentlig i 7 uger, 2 ugers pause og dag 1,8, 15 i 4 ugers cyklus N=199 Gemcitabin som kontrol + cisplatin ugentlig 25mg/m2 N=201
28 ADVANCED DISEASE A randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy naive advanced pancreatic adenocarcinoma: The GIP 1 (Gruppo Italiano Pancreas GOIM/GISCAD/GOIRC) study. Di Miao Gem Gem/Cis OS 1 year survival PFS Anæmi Trombocytopeni 8,3 mdr. 34,0 % 3,9 mdr. 39% 29% 7,2 mdr. 30,7 % 3,8 mdr. 50% 57% Alle endepunkter insignifikante Subgruppeanalyse af PS 0: Signifikant negativ effekt! Tidligere meta analyse, som viste effekt af Gem platin kombinationer, nu insignifikant efter inklusion af dette studium
29 ADVANCED DISEASE Combination chemotherapy and effect according to performance status Heinemann et al., BMC Cancer 2008
30 PA.3 study: Gem-erlotinib erlotinib Overall survival ADVANCED DISEASE Survival probability Tarceva TM + gemcitabine Placebo + gemcitabine HR=0.79* (95% CI, ), P=0.011 (*adjusted for PS and extent of disease at randomization) Tarceva / gemcitabine (n=285) Placebo/ gemcitabine (n=284) Median survival (months) year survival 24% 17% Survival (months) Moore et al., JCO 2007
31 PA.3 study, Hazard ratios for survival ADVANCED DISEASE HR 95% CI n Factors Tarceva:placebo Performance status 0-1 Performance status 2 Locally advanced Distant metastasis Pain 20 Pain >20 Male Female Age <65 Age 65 United States Canada Rest of World HER1/EGFR positive HER1/EGFR negative HER1/EGFR unknown Moore et al., JCO
32 ADVANCED DISEASE PA.3 study, Adverse events Tarceva (%) n=282 Placebo (%) n=280 Events Any Grade 3,4 Any Grade 3,4 Rash Diarrhoea Infection Stomatitis 23 < Pneumonitis <1 Fatigue Moore et al., JCO 2007
33 ADVANCED DISEASE Accetable standard systemic treatment options 2009 GEM alone GEM-erlotinib registred for metastatic PC only, mos + 12 days, some additional toxicity GEM-CAP mos + 1 month, only significant in meta-analysis analysis GEM-platinum? doubtful effect - now not significant in meta- analysis, significant toxicity
34 SUPPORTIVE CARE
35 SUPPORTIVE CARE Forebyggelse af venøse tromboemboliske events (VTE) ved pancreascancer
36 SUPPORTIVE CARE GONKO 004 trial A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. H.Reiss et al. ASCO 2009 Baggrund: VTE forekommer hos ca. 10% af patienter med PC Formål: Undersøge effekt af LMWH (Klexane) i kombination med kemoterapi mht. frekvens af VTE og mos Inklusion: Avanceret PC, ikke tidligere kemoterapi Karnofsky PS > 60 Ingen større blødning indenfor 2 uger, ingen VTE indenfor 2 år
37 SUPPORTIVE CARE A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. H.Reiss et al. ASCO 2009 Antal af VTE: 15/152 i observation 2/160 i LMWH
38 SUPPORTIVE CARE A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial. H.Reiss et al. Konklusion: LMWH er effektiv og sikker behandling til forebyggelse af VTE hos patienter med pancreascancer. Endelige resultater på mos og mttp afventes
39 SUPPORTIVE CARE Treatment of malignant ascites
40 SUPPORTIVE CARE Heiss M, et al. Catumaxomab a new treatment option for patients with malignant ascites.. Ann. Oncol.;20:Suppl. 7, 2009 Catumaxomab: Trifunctional antibody, 4 infusions i.p.. over 6 h in ascending doses Multicenter, randomized, open-label phase II/III study 258 pts with symptomatic malignant ascites due to epithelial cancer
41 SUPPORTIVE CARE Heiss M, et al. Catumaxomab a new treatment option for patients with malignant ascites.. Ann. Oncol.;20:Suppl. 7, 2009 Subgroup analysis of 129 ovarian and 129 non- ovarian (gastric, pancreatic, CRC etc.) cancer patients randomized AEs: : Cytokine release related symptoms in 80%, mostly short-lasting and of grade Median puncture-free survival (days) Nonovarian cancer Ovarian cancer Catumaxomab Placebo 2p <
42 Pancreatic islet cell tumours Pancreatic NET
43 Pancreatic NET Raymond E, et al. Phase III, randomized, double-blind blind trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic islet cell tumours.. Ann. Oncol.;20:Suppl. 7, 2009 Sunitinib: : Oral, multitargeted tyrosine kinase inhibitor used for mrcc and GIST Phase II-study of sunitinib in NET 1 : ORR of 16.7% in 66 pts with pnet 1) Kulke MH, et al. JCO; 26: , 2008
44 Pancreatic NET Raymond E, et al. Phase III, randomized, double-blind blind trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic islet cell tumours.. Ann. Oncol.;20:Suppl. 7, 2009 Local, locally advanced, or metastatic, well-differentiated pnet not amenable to curative therapy and with disease progression in the prior 12 months Primary end point PFS Sunitinib 37.5 mg/day or placebo
45 Pancreatic NET Raymond E, et al. Phase III, randomized, double-blind blind trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic islet cell tumours.. Ann. Oncol.;20:Suppl. 7, pts randomized Toxicity events, sunitinib Diarrhea, nausea, vomiting, asthenia, fatigue Grade 3-43 neutropenia (12%), hypertension (9%), diarrhea (7%), hypoglycemia (7%), palmar-plantar plantar erythrodysesthesia (7%)
46 Pancreatic NET Raymond E, et al. Phase III, randomized, double-blind blind trial of sunitinib versus placebo in patients with progressive, well-differentiated pancreatic islet cell tumours.. Ann. Oncol.;20:Suppl. 7, 2009 Interim analysis with 73 events 5 deaths in sunitinib arm vs 15 in placebo arm Study halted early and patients on placebo given the opportunity to cross over to sunitinib Median progression free survival (months) Placebo Sunitinib HR 0.397, 2p <0.001
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Background. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
Activity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
Trials in Elderly Melanoma Patients (with a focus on immunotherapy)
Trials in Elderly Melanoma Patients (with a focus on immunotherapy) Where we were Immunotherapy Trials: past and present Relevance for real world practice Where we are SIOG October 2012 James Larkin FRCP
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Philippe RUSZNIEWSKI
NOUVEAUTES THERAPEUTIQUES DANS LES TUMEURS NEUROENDOCRINES DIGESTIVES (Radiothérapie vectorisée et loco-régionale exclue) Réunion APRAMEN, Paris, 2 février 2013 Philippe RUSZNIEWSKI Pôle des Maladies de
New Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
Come è cambiata la storia naturale della malattia
Malattia Metastatica del Carcinoma del Grosso Intestino Tecniche e terapie Innovative Come è cambiata la storia naturale della malattia Antonio Frassoldati Oncologia Clinica - Ferrara 29 ottobre 2011 Colorectal
Advances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
National Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
IMMUNOMEDICS, INC. February 2016. Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases February 2016 Forward-Looking Statements This presentation, in addition to historical information, contains certain
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 2002 ORLANDO : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group In the 2002 edition of the ASCO meeting, a total of 315 abstracts in the field of respiratory
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015
pan-canadian Oncology Drug Review Initial Clinical Guidance Report Ramucirumab (Cyramza) for Gastric Cancer September 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 18 September 2015 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
Approccio multidisciplinare nel carcinoma della vescica. D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU)
Approccio multidisciplinare nel carcinoma della vescica D. Amoroso Dip. di Oncologia Medica Ospedale Versilia Lido di Camaiore (LU) Disclosures Advisory Role, Honoraria: ü Roche ü Italfarmaco Outline v
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
How valuable is a cancer therapy? It depends on who you ask.
How valuable is a cancer therapy? It depends on who you ask. Comparing and contrasting the ESMO Magnitude of Clinical Benefit Scale with the ASCO Value Framework in Cancer Ram Subramanian Kevin Schorr
Scottish Medicines Consortium
Scottish Medicines Consortium pemetrexed 500mg infusion (Alimta ) No. (192/05) Eli Lilly 8 July 2005 The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS
Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma. Claire Vines, 2016 Pharm.D. Candidate
+ Anti-PD1 Agents: Immunotherapy agents in the treatment of metastatic melanoma Claire Vines, 2016 Pharm.D. Candidate + Disclosure I have no conflicts of interest to disclose. + Objectives Summarize NCCN
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012. (minutes for web publishing)
Cancer Treatments Subcommittee of PTAC Meeting held 2 March 2012 (minutes for web publishing) Cancer Treatments Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
Emerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
Clinical Spotlight in Breast Cancer
2015 European Oncology Congress in Vienna Clinical Spotlight in Breast Cancer Reference Slide Deck Abstract #1815 Impact of Palbociclib Plus Fulvestrant on Global QOL, Functioning, and Symptoms Compared
Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer
Pharmacogenomic markers in EGFR-targeted therapy of lung cancer Rafal Dziadziuszko, MD, PhD University of Colorado Cancer Center, Aurora, CO, USA Medical University of Gdansk, Poland EMEA Workshop on Biomarkers,
Treatment Paradigm in NSCLC Treatment
Treatment Paradigm in NSCLC Treatment Era of Targeted Therapy Aumkhae Sookprasert, MD Medicine Department, KKU Which factors taken to be account in NSCLC treatment? 1. Staging 2. ECOG performance status
New Trends & Current Research in the Treatment of Lung Cancer, Pt. II
New Trends & Current esearch in the Treatment of Lung Cancer, Pt. II Howard (Jack) West, MD President & CEO, GACE Medical Director, Thoracic Oncology Program Swedish Cancer Institute Seattle, WA Cancer
January 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue)
Sur les nouveaux médicaments et les perspectives qu ils offrent (traitement à la carte et survie longue) Professeur Jean Trédaniel Unité de cancérologie thoracique Hôpital Saint-Louis Comparison of Four
Prior Authorization Guideline
Prior Authorization Guideline Guideline: PS Inj - Alimta Therapeutic Class: Antineoplastic Agents Therapeutic Sub-Class: Antifolates Client: PS Inj Approval Date: 8/2/2004 Revision Date: 12/5/2006 I. BENEFIT
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
Drug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
Avastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
Cancer Treatment Reviews
Cancer Treatment Reviews xxx (2011) xxx xxx Contents lists available at SciVerse ScienceDirect Cancer Treatment Reviews journal homepage: www.elsevierhealth.com/journals/ctrv Antitumour treatment Systemic
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer?
What is the optimal sequence of anti-her2 therapy in metastatic breast cancer? David Miles Mount Vernon Cancer Centre Northwood Middlesex UKBCM mee)ng: London 2013 Herceptin plus a taxoid extends survival
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
Before, Frank's immune cells could
Before, Frank's immune cells could barely recognize a prostate cancer cell. Now, they are focused on it. Stimulate an immune response against advanced prostate cancer Extend median survival beyond 2 years
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
U.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
Locally advanced and bordeline forms of pancreatic cancer
19 May 2011 Locally advanced and bordeline forms of pancreatic cancer P r Pascal Hammel Pôle des Maladies de l Appareil Digestif Hôpital Beaujon, 92110 Clichy Université Paris VII, Denis Diderot pascal.hammel@bjn.aphp.fr
REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group
1 REPORT ASCO 2011 CHICAG0 : RESPIRATORY ONCOLOGY Johan Vansteenkiste / Christophe Dooms, Univ. Hospital Leuven and Leuven Lung Cancer Group 10 MESSAGE HIGHLIGHTS Early stage non-small cell lung cancer
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials
Pancreatic Cancer: FDA Approved Treatments and Clinical Trials Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat 2 Pancreatic cancer:
Ching-Yao Yang, Yu-Wen Tien
Ching-Yao Yang, Yu-Wen Tien Division of General Surgery, Department of Surgery, National Taiwan University Hospital Oct-30-2010 Pancreatic NET have poorer prognosis when presence of liver metastases at
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW. FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012
Background LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW FOLFIRINOX for first line treatment of advanced pancreatic cancer January 2012 The incidence of pancreatic cancer in the UK is 9.4/100,000. It is
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany
Targeting angiogenesis in NSCLC: Clinical trial update Martin Reck Lung Clinic Grosshansdorf Grosshansdorf, Germany This presentation was selected by the 15 th World Conference on Lung Cancer Program Committee
Chapter 7: Lung Cancer
Chapter 7: Lung Cancer Contents Chapter 7: Lung Cancer... 1 Small Cell... 2 Good PS + Limited stage... 2 Cisplatin/etoposide... 2 Concurrent chemotherapy + XRT... 2 Good / Intermediate PS... 2 Carboplatin
Dr Peter Briggs Medical Oncologist. Lung Cancer & Mesothelioma: is it worth treating?
Dr Peter Briggs Medical Oncologist Lung Cancer & Mesothelioma: is it worth treating? GOALS OF CANCER THERAPY CURE Good chance Medium chance Low chance PALLIATION Life prolonging Symptomatic improvement
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
DECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Crizotinib as 2nd line treatment for patients with anaplastic lymphoma kinase (ALK) positive lung cancer Score The application
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba
Carcinoma papilar renal, cromófobo y otras histologías. Maria José Méndez Vidal Servicio de oncología Medica Hospital Reina Sofía Córdoba Europe 121 629 new cases RCC 2012, 75 676 affected men Slide 3
Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
September 27, 2013 ONO PHARMACEUTICAL CO., LTD. Corporate Communications Phone: +81-6-6263-5670 Decision to Continue the Development of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer to be Announced
Evaluation of perioperative chemotherapy for operable gastroesophageal and gastric cancer In western Denmark June 2008- August 2010
Evaluation of perioperative chemotherapy for operable gastroesophageal and gastric cancer In western Denmark June 2008- August 2010 Anders Christian Larsen,md. Phd student Department of Surgery and Oncology
New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough?
New developments and controversies in breast cancer treatment: PARP Inhibitors: a breakthrough? F. Cardoso, MD Champalimaud Cancer Center Lisbon, Portugal BBM 2010 Thank you to A Tutt & PRIME Oncology
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development
Ovarian Cancer and Modern Immunotherapy: Regulatory Strategies for Drug Development Sanjeeve Bala, MD, MPH Ovarian Cancer Endpoints Workshop FDA White Oak September 3, 2015 Overview Immune agents from
New Targets and Treatments for Follicular Lymphoma. Disclosures
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Disclosures Consulting fees from:
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
Department of Veterans Affairs Health Services Research & Development Service Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost-Effectiveness
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Strength of Study End Point(s): Progression-free survival
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Paclitaxel for the First-line Treatment of Metastatic Breast Cancer Drug/Drug Combination: Bevacizumab and
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer
News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck
Management of Platinum-Sensitive Recurrent Ovarian Cancer
Management of Platinum-Sensitive Jacobus Pfisterer a and Jonathan A. Ledermann b The majority of patients with ovarian cancer will relapse despite state-of-the-art first-line surgery and chemotherapy.
Kanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC)
Issues Concerning Development of Products for Treatment of Non-Metastatic Castration- Resistant Prostate Cancer (NM-CRPC) FDA Presentation ODAC Meeting September 14, 2011 1 Review Team Paul G. Kluetz,
Targeterbare mutationer / biomarkører Status og udfordringer for patologien
Targeterbare mutationer / biomarkører Status og udfordringer for patologien Birgit Guldhammer Skov overlæge, dr.med. Patologi afdelingen Rigshospitalet Biomarkers lung cancer Last 3-5 years More and more
Clinical Study Report
An Open, Multi-Center, Phase II Clinical Trial to Evaluate Efficacy and Safety of Taxol (), UFT, and Leucovorin in Patients with Advanced Gastric Cancer Clinical Study Report 4F, No. 156, Jiankang Rd.,
Avastin in Metastatic Breast Cancer
Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche
The role of PARP inhibitors in high grade serous ovarian cancers
The role of PARP inhibitors in high grade serous ovarian cancers Jonathan Ledermann UCL Cancer Institute University College London ANZGOG-ASGO, Canberra, March 214 Cancer Research UK UCL Centre DNA Repair
COMMISSIONING. for ULTRA-RADICAL SURGERY ADVANCED OVARIAN CANCER
COMMISSIONING for ULTRA-RADICAL SURGERY in ADVANCED OVARIAN CANCER WHY THIS MUST HAPPEN PERSPECTIVE COMMISSIONING FOR WHO, FOR WHAT? Biological Basis Surgical Basis International and national standards
MAINTENANCE CHEMOTHERAPY
1 MAINTENANCE CHEMOTHERAPY FOR ADVANCED NSCLC Dr.M.V.Nagarjuna OBJECTIVES OF THIS SEMINAR 1. Definitions 2. Switch maintenance 3. Continuation Maintenance 4. Immunotherapy as maintenance 5. Conclusions
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY. Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds
NEW CLINICAL RESEARCH OPTIONS IN PANCREATIC CANCER IMMUNOTHERAPY Alan Melcher Professor of Clinical Oncology and Biotherapy Leeds CANCER IMMUNOTHERAPY - Breakthrough of the Year in Science magazine 2013.
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
(1)Faivre-Finn C, Bouvier AM, Mitry E et al. Chemotherapy for colon cancer in a well-defined French population: is it under- or over-prescribed?
Colorectal cancer Chemotherapy for the elderly Dr Christophe TOURNIGAND Hôpital Saint Antoine France Hôpital Charles Lemoyne - Quebec GERCOR EPOG - UPMC Colorectal cancer ( CRC) : an Elderly Disease 3rd
Treatment Approaches for Pancreatic Cancer
Treatment Approaches for Pancreatic Cancer January 8, 2015 If you experience technical difficulty during the presentation: Contact WebEx Technical Support directly at: US Toll Free: 1-866-229-3239 Toll
Understanding Clinical Trials HR =.6 (CI :.51.7) p BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT )
BCCA Protocol Summary for Palliative Treatment of Advanced Pancreatic Neuroendocrine Tumours using SUNItinib (SUTENT ) Protocol Code Tumour Group Contact Physician UGIPNSUNI Gastrointestinal Dr. Hagen
the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015
Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers
Nieuwe ontwikkelingen op het gebied van de angiogeneseremmers Emile Voest, MD, PhD Department of Medical Oncology University Medical Center Utrecht the Netherlands 4e Nascholing Targeted Therapy April
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
Lung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
Medication Policy Manual. Topic: Alimta, pemetrexed Date of Origin: May 12, 2010
Medication Policy Manual Policy No: dru213 Topic: Alimta, pemetrexed Date of Origin: May 12, 2010 Committee Approval Date: February 17, 2015 Next Review Date: February 2016 Effective Date: March 1, 2015
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Active centers: 2. Number of patients/subjects: Planned: 20 Randomized: Treated: 20 Evaluated: Efficacy: 13 Safety: 20
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
Palliative Care and Phase I Cancer Trials: Irrelevance, Antagonism, or Synergy?
Palliative Care and Phase I Cancer Trials: Irrelevance, Antagonism, or Synergy? J. Brian Cassel, PhD, Erin Alesi, MD, Haeseong Park, MD, Margaret Henderson, MLS AHIP, Andrew Poklepovic, MD, Egidio Del
2. Background This was the fourth submission for everolimus requesting listing for clear cell renal carcinoma.
PUBLIC SUMMARY DOCUMENT Product: Everolimus, tablets, 5 mg and 10 mg, Afinitor Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: November 2011 1. Purpose of Application To
Columbia University Mesothelioma Applied Research Foundation - 2009 - www.curemeso.org. Mesothelioma Center www.mesocenter.org
Columbia University Mesothelioma Center www.mesocenter.org Multimodal clinical trials, treatment (surgery, radiation, chemotherapy) Peritoneal mesothelioma program Immunotherapy translational, experimental
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003)
Lenalidomide (LEN) in Patients with Transformed Lymphoma: Results From a Large International Phase II Study (NHL-003) Reeder CB et al. Proc ASCO 2010;Abstract 8037. Introduction > Patients (pts) with low-grade
Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics
EPAAC WP8 Research Forum - 2 July, Sofitel Hotel Europe, Brussels Public-Private Partnerships in early phase clinical research: Spurring access to innovative therapeutics JY Blay, Past President EORTC
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness
Treatment of Metastatic Non-Small Cell Lung Cancer: A Systematic Review of Comparative Effectiveness and Cost Effectiveness Investigators: Paul G. Shekelle, MD, PhD, Director Alicia R. Maher, MD Clinical